Value of serum miRNA-122 and Wisteria floribunda agglutinin-positive Mac-2 binding protein in predicting fibrosis degree in patients with chronic viral hepatitis
-
摘要: 目的探讨血清miRNA-122和紫藤多花凝集素阳性Mac-2结合蛋白(WFA+-M2BP)在慢性病毒性肝炎患者肝纤维化程度预测中的应用价值。方法选取2015年3月-2016年6月汉中市中心医院收治的行肝穿刺活组织检查的慢性乙型肝炎患者98例(CHB组)、慢性丙型肝炎患者104例(CHC组)和健康对照者56例(对照组)。实时荧光定量聚合酶链反应(real timePCR)检测3组血清miRNA-122水平。HISCL M2BPGi检测系统检测血清WFA+-M2BP水平。计量资料2组间比较采用t检验,计数资料组间比较采用χ2检验。采用受试者工作特征曲线(ROC曲线)分析血清miRNA-122和WFA+-M2BP在肝炎患者肝纤维化程度中的预测价值,多因素联合分析采用logistic回归预测概率。结果 CHB组和CHC组血清miRNA-122(t值分别为39.437、11.460,P值分别为<0.001和0.005)和WFA+-M2BP(t值分别为12.885、18.500,P值分别为0.004、0....Abstract: Objective To investigate the clinical value of serum miRNA-122 and Wisteria floribunda agglutinin-positive Mac-2 binding protein (WFA+-M2BP) in predicting fibrosis degree in patients with chronic viral hepatitis.Methods A total of 98 patients with chronic hepatitis B (CHB group) and 104 patients with chronic hepatitis C (CHC group) , who were admitted to Hanzhong Municipal Hospital from March 2015 to June 2016 and underwent liver biopsy, were enrolled, and 56 healthy subjects were enrolled as control group.Quantitative real-time PCR was used to measure the serum level of miRNA-122 for all groups, and HISCL M2BPGi was used to measure the serum level of WFA+-M2BP.The t-test was used for comparison of continuous data between groups and the chi-square test was used for comparison of categorical data between groups.The receiver operating characteristic (ROC) curve was used to analyze the value of serum miRNA-122 and WFA+-M2BP in predicting fibrosis degree in patients with hepatitis, and the logistic regression model was used to perform multivariate analysis and predict probability.Results Compared with the control group, the CHB group and the CHC group had significantly higher serum levels of miRNA-122 (t = 39.437 and 11.460, P < 0.001 and P = 0.005) and WFA+-M2BP (t = 12.885 and 18.500, P = 0.004 and 0.002) .In the CHB group, the patients with S1-2 fibrosis had a significantly higher serum level of miRNA-122 than those with S3-4 fibrosis (t = 11.795, P = 0.006) .In the CHB group and the CHC group, the patients with S1-2 fibrosis and G1-2 liver inflammatory activity had a significantly lower serum level of WFA+-M2BP than those with S3-4 fibrosis (t = 8.584 and 3.565, P = 0.016 and 0.031) and G3-4 liver inflammatory activity (t = 5.568 and 3.354, P = 0.022 and 0.048) .The ROC curve analysis showed that miRNA-122 and WFA+-M2BP had a high efficiency in predicting fibrosis degree in CHB patients, while WFA+-M2BP had a high efficiency in predicting fibrosis degree in CHC patients (P < 0.05) ; miRNA-122 combined with WFA+-M2BP had a high efficiency in predicting fibrosis degree in CHB and CHC patients (area under the ROC curve > 0.9, all P = 0.001) .Conclusion Serum miRNA-122 combined with WFA+-M2BP can be used to predict fibrosis degree in both CHB and CHC patients.
-
Key words:
- hepatitis B, chronic /
- hepatitis C, chronic /
- liver cirrhosis /
- microRNAs /
- plant lectins
-
[1]FUJIWARA N, FRIEDMAN SL, GOOSSENS N, et al.Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine[J].J Hepatol, 2017.[Epub ahead of print] [2]LIANG XE, WANG Y, HOU JL.Quantitative assessment of liver fibrosis:invasive or non-invasive?[J].J Clin Hepatol, 2015, 31 (3) :317-321. (in Chinese) 梁携儿, 汪艳, 侯金林.肝纤维化定量诊断:有创还是无创?[J].临床肝胆病杂志, 2015, 31 (3) :317-321. [3]DU JH, NAN YM.Novel molecular diagnostic markers for liver fibrosis[J].J Clin Hepatol, 2017, 33 (3) :445-450. (in Chinese) 杜静华, 南月敏.肝纤维化新型分子诊断标志物[J].临床肝胆病杂志, 2017, 33 (3) :445-450. [4]HUANG CI, HUANG CF, YEH ML, et al.Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein expression predicts disease severity in chronic hepatitis C patients[J].Kaohsiung J Med Sci, 2017, 33 (8) :394-399. [5]Chinese Society of Hepatology, Chinese Society of Infectious Diseases, Chinese Medical Association.The guideline of prevention and treatment for chronic hepatitis B (2010 version) [J].J Clin Hepatol, 2011, 27 (1) :I-XVI. (in Chinese) 中华医学会肝病学分会, 中华医学会感染病学分会.慢性乙型肝炎防治指南 (2010版) [J].临床肝胆病杂志, 2011, 27 (1) :I-XVI. [6]Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association.The guideline of prevention and treatment for hepatitis C:a 2015 update[J].J Clin Hepatol, 2015, 31 (12) :1961-1979. (in Chinese) 中华医学会肝病学分会, 中华医学会感染病学分会.丙型肝炎防治指南 (2015年更新版) [J].临床肝胆病杂志, 2015, 31 (12) :1961-1979. [7]STERLING RK, LISSEN E, CLUMECK N, et al.Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV confection[J].Hepatology, 2006, 43 (6) :1317-1325. [8]WAI CT, GREENSON JK, FONTANA RJ, et al.A simple noninvasive indexcan predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C[J].Hepatology, 2003, 38 (2) :518-526. [9]Chinese Society of Infectious Diseases and Parasitology, Chinese Society of Hepatology, Chinese Medical Association.Prevention and treatment of viral hepatitis[J].Chin J Infect Dis, 2001, 19 (1) :56-62. (in Chinese) 中华医学会传染病与寄生虫病学分会、肝病学分会.病毒性肝炎防治方案[J].中华传染病杂志, 2001, 19 (1) :56-62. [10]ZHANG Q, LIU J, GAO XH.Detection of miRNA-122 expression in serum exosome in patients with HCV infection and its clinical significance[J].Chin J Clin Infect Dis, 2016, 9 (5) :439-443. (in Chinese) 张庆, 刘杰, 高晓红.HCV感染者中血清外泌体miRNA-122的检测及其临床意义[J].中华临床感染病杂志, 2016, 9 (5) :439-443. [11]KUNO A, IKEHARA Y, TANAKA Y, et al.A serum“sweetdoughnut”protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitis[J].Sci Rep, 2013, 3:1065-1073. [12]MA YH, XING HC.Advances of microRNA on liver fibrosis[J/CD].Chin J Liver Dis:Electronic Edition, 2017, 9 (2) :1-4. (in Chinese) 马艳华, 邢卉春.microRNAs在肝纤维化中的研究进展[J/CD].中国肝脏病杂志:电子版, 2017, 9 (2) :1-4. [13]MAK KM, MEI R.Basement membrane type IV collagen and laminin:an overview of their biology and value as fibrosisbiomarkers of liver disease[J].Anat Rec (Hoboken) , 2017, 300 (8) :1371-1390. [14]MA YH, HAN M, FENG SH, et al.Differential expression of plasma microRNA in patients with HBV-related liver fibrosis[J/CD].Chin J Liver Dis:Electronic Edition, 2017, 9 (1) :20-26. (in Chinese) 马艳华, 韩铭, 冯胜虎, 等.HBV相关肝纤维化患者血浆microRNA的差异表达[J/CD].中国肝脏病杂志:电子版, 2017, 9 (1) :20-26. [15]MU MY, LI Y, YANG WF, et al.Research progress of microRNA-122 in hepatitis B virus infection and related diseases[J].J Med Res, 2015, 44 (1) :154-158. (in Chinese) 穆茂媛, 李滢, 杨方万, 等.microRNA-122在乙型肝炎病毒感染及相关疾病中的研究进展[J].医学研究杂志, 2015, 44 (1) :154-158. [16]JIANG DF, XING TJ, HUANG JX, et al.Expression and clinical significance of miR-122 and 29 in the hepatitis B virus-related liver disease[J/CD].Chin J Clinicians:Electronic Edition, 2013, 7 (3) :1085-1089. (in Chinese) 姜丹凤, 邢同京, 黄俊星, 等.微小RNA-122和29在乙型肝炎病毒感染相关肝病中的表达及临床意义[J/CD].中华临床医师杂志:电子版, 2013, 7 (3) :1085-1089. [17]NAKAMURA M, KANDA T, JIANG X, et al.Serum microRNA-122 and Wisteria floribundaagglutinin-positive Mac-2 binding protein areuseful tools for liquid biopsy of the patientswith hepatitis B virus and advanced liverfibrosis[J].PLo S One, 2017, 12 (5) :e0177302. [18]HASEGAWA K, TAKATA R, NISHIKAWA H, et al.Impact of wisteria floribunda agglutinin-positive Mac-2-binding protein in patients with hepatitis C virus-related compensated liver cirrhosis[J].Int J Mol Sci, 2016, 17 (9) :1500.
本文二维码
计量
- 文章访问数: 2517
- HTML全文浏览量: 23
- PDF下载量: 498
- 被引次数: 0